| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. | Tannock IF, et al./ N Engl J Med. 2004;351(15):1502-12. |
| Phase II study with the combination of capecitabine (C) and vinorelbine i(V) n metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes | L. Estevez et al. / ASCO-2004 |
| Phase II study of capecitabine a (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage) | M. Bellet et al./ ASCO-2004 |
| Phase II study with the combination of capecitabine (C) and vinorelbine i(V) n metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes | L. Estevez et al./ ESMO-2004 |
| Phase II study of capecitabine a (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage) | M. Bellet et al./ ESMO-2004 |
| Phase II study of capecitabine (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage). Correlation between clinico-pathological response and fluoropyrimidine-enzyme profile. Early results | M. Bellet et al./ ASCO-2005 |
| Docetaxel followed by capecitabine as first-line chemotherapy in metastatic breast cancer patients: preliminary results | Dr. Bayo et al./ ASCO-2005 |
| Induction (I) or consolidation (C) chemotherapy with docetaxel (D) and gemcitabine (G) plus concomitant chemoradiotherapy (CT/TRT) with docetaxel and carboplatin (Cb) for unresectable stage III non-small cell lung cancer (NSCLC) patients (p). Initial report of the randomized phase II trail SLCG 0008 | P. Garrido & GECP/ ASCO-2005 |
| Phase II/III Trial Induction Chemotherapy (ICT) with Cisplatin/5-Fluoruracil (PF) vs. Docetaxel (T) plus PF (TPF) followed by chemoradiotherapy (CRT) vs. CRT for Unresectable Locally Advanced Head and Neck Cancer(LAHNC) | R. Hitt & TTCC/ ASCO-2005 |
| Toxicity and health-related quality of life (HRQoL) in node negative breast cancer (BC) patients (pts)receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC ( 5-fluoruracil, doxorubicin, cyclophosphamide): Impact of adding prophylactic growth factors ( GF) to TAC. GEICAM Study 9805 | M. Martín & GEICAM/ ASCO-2005 |
| Pharmacogenetic study in patients (pt) with metastatic breast (BC) and colorectal cancer (CRC) treated with capecitabina (C) | Dr. Alba et al./ ASCO-2005 |
| Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study | Dr. Sastre et al./ JClinOncol 2005 May 20; 23 (15): 3545-3551 |
| Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer | Dr. Quintela-Fandino/Dra. Grávalos/ Anticancer Drugs. 2005 Jan;16(1):31-8. |
| Guides for adjuvant treatment of colon cancer | Aranda E./ Clin Transl Oncol 2006; 8(2):98-102 |
| A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. | Navarro M./Int J Radiat Oncol Biol Phys 2006 Sep 1; 66(1):201-5 |
| Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). | R. Hitt et al. / ASCO-2006 |
| Estudio asistencial de la combinación de Capecitabina con Carboplatino administrados cada dos semanas en pacientes con cancer de mama metastasico | I. Chacon et al./ ASCO 2006 |
| Docetaxel (T) followed by capecitabine (X) as first-line chemotherapy in patients (pts) with metastatic breast cancer (MBC): Preliminary findings from a phase II study | JL. Bayo et al./ ASCO 2006 |
| Phase II study of capecitabine (X) + docetaxel (T) as neoadjuvant treatment in patients (pts) with locally advanced breast cancer (LABC) including biological correlates. | M. Bellet et al./ ASCO-2006 |
| Phase II study of capecitabine (X) in combination with vinorelbine (N) in patients (pts) with pretreated metastatic breast cancer (MBC). | N. Batista et al/ ASCO-2006 |
| Estudio Fase II randomizado del tratamiento continuo versus tratamiento estandar con capecitabina en pacientes con cáncer de mama metastásico. | M. Martin et al./ ESMO-2006 |
| Randomized phase II trial of radiotherapy with or without Erlotinib in patients with locally advanced or unresectable non small cell lung cancer | E. Martinez/ XI Congreso nacional SEOM, Clin Transl Oncol, vol9, extraordinary 2, Oct 2007: P-141 |
| Randomized phase II trial of radiotherapy with or without Erlotinib in patients with locally advanced or unresectable non small cell lung cancer | E. Martinez/ ASTRO 49th Annual Meeting;2007 |
| Randomized phase II trial of radiotherapy with or without Erlotinib in patients with locally advanced or unresectable non small cell lung cancer | E. Martinez/ 12th WCLC Journal of Thoracic Oncology, vol2, nº8, supplement 4: P3-113 |
| Feasibility and tolerability of the addition of erlotinib to 3D thoracic radiotherapy (RT) in patientes with unresectable NSCLC: a prospective randomized phase II study | E. Martinez et al./ ASCO 2008 |
| Adjuvant Chemotherapy with sequential or concurrent Anthracycline and Docetaxel: Breast International Group 02-98 randomized trial | Francis P/J Natl Cancer Inst 2008;100:121-133 |
| A multicenter phase II study to evaluate the sequential Docetaxel followed by Capecitabine treatment in anthracycline pretreated HER-2 negative patients with metastatic breast cancer | J. Bayo et al./ JClin Transl Oncol 2008 |
| A phase II study of weekly vinorelbine and trastuzumab in patients with HER-2 positive metastatic breast cancer | Bayo-Calero JL et al./ Clin Breast Cancer 2008 Jun; 8(3): 264-8 |
| Randomized study of weekly irinotecan lus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5 fluorouracil/leucovorin (FOLFIRI), as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish cooperative group for the treatment of digestive tumors study | E. Aranda/ Ann. Onc., February 2009; 20: 251 - 257 |
| Final results of a randomized Phase III trial comparing induction chemotherapy (ICT) with cisplatin/5-FU (PF) or docetaxel/cisplatin/5-FU (TPF) followed by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC) | Dr Hitt Ret al.& Spanish Head and Neck Cancer Cooperative Group, Spain/ ASCO-2009 |
| Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group | P Garcia-Alfonso et al./ Br J Cancer 2009; 101: 1039–1043.
|
Inicio
